Compare SHPH & ORIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SHPH | ORIS |
|---|---|---|
| Founded | 2012 | 2014 |
| Country | United States | China |
| Employees | N/A | 69 |
| Industry | Biotechnology: Pharmaceutical Preparations | Farming/Seeds/Milling |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1M | 3.2M |
| IPO Year | 2022 | N/A |
| Metric | SHPH | ORIS |
|---|---|---|
| Price | $0.70 | $0.61 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 133.1K | ★ 1.4M |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $152.96 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.12 | $0.06 |
| 52 Week High | $5.59 | $1.87 |
| Indicator | SHPH | ORIS |
|---|---|---|
| Relative Strength Index (RSI) | 37.73 | 40.33 |
| Support Level | $0.50 | $0.11 |
| Resistance Level | $1.06 | $1.08 |
| Average True Range (ATR) | 0.11 | 0.14 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 41.68 | 22.12 |
Shuttle Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company leveraging its proprietary technology to develop novel therapies designed to cure cancers. The company's goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy (RT) is one of the effective modalities for treating cancers. It is developing a pipeline of products designed to address the limitations of the current cancer therapies as well as to extend to the new applications of RT. The company believes that its product candidates will enable the company to deliver cancer treatments that are safer, more reliable and at a greater scale than that of the current standard of care.
Oriental Rise Holdings Ltd is an integrated supplier of tea products in China. It is principally engaged in the business of planting, cultivating, processing, and selling processed tea. The company currently produces and sells three categories of products: roughly processed white tea, roughly processed black tea, and refined tea. The company's business operations are vertically integrated, covering cultivation, processing of tea leaves, and the sale of tea products to tea business operators and end-user retail customers. Geographically, the company generates all of its revenue from its business in the People's Republic of China (the PRC).